Ophelia Venturelli

University Of Wisconsin-Madison

$5,729,580

Attributed

$9,130,865

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.5M · FY2017–25

$5M$3.8M$2.5M$1.3M$0

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$9,130,865 · 5

By mechanism

R01$5,854,973 · 2

R35$2,420,850 · 1

R21$855,042 · 2

Top collaborators

Most similar at University Of Wisconsin-Madison

Same institution · by research overlap

Luigi Puglielli$13,206,203
Federico E Rey$8,049,349
Robert F Kalejta$11,761,648
Lloyd M Smith$20,685,320
Rupa Sridharan$4,639,708

Others in their field

Other Emerging Leaders on “Gut Microbiome”

Gary Fanger · Rise Therapeutics, Llc$13,091,747
Dong Wang · Harvard School Of Public Health$10,296,766
Akila Subramaniam · University Of Alabama At Birmingham$6,547,544
John Patrick Haran · Univ Of Massachusetts Med Sch Worcester$6,321,309
Chun-Jun Guo · Weill Medical Coll Of Cornell Univ$6,180,583
Mingyang Song · Massachusetts General Hospital$5,845,390

Research focus

Gut MicrobiomeGut MicrobiotaComplexCommunitiesDesignMemberMicrobiomeMicrobial CommunityPhenotypeResponseLeadEcosystemPhysiologyMicrobialBehaviorPathogenMediatingGeneticButyratesMedicineComputer ModelsCellsProbioticsStructure

Grant awards (17)

Dietary Fiber-Microbiome Interactions: Elucidating Mechanisms to Suppress Multi-Drug Resistant Organisms in the Human Gut$3,012,181

R01 · FY2025 · AI · contact PI

A multi-scale systems biology framework for understanding and engineering the human gut microbiome$509,125

R35 · FY2025 · GM · contact PI

Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease$641,475

R01 · FY2023 · EB · contact PI

Administrative Supplement: Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease$175,000

R01 · FY2023 · EB · contact PI

Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease$661,600

R01 · FY2022 · EB · contact PI

Elucidating ecological mechanisms for propagation of antibiotic resistance genes via massively parallelized single-cell sequencing$233,250

R21 · FY2022 · AI · contact PI

Large-scale profiling of microbial and metabolic interactions between C. difficile and gut microbiota using ultrahigh-throughput droplet microfluidics$233,250

R21 · FY2022 · AI · contact PI

Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease$667,219

R01 · FY2021 · EB · contact PI

Elucidating the molecular and ecological design principles of stability and assembly of the human gut microbiota$382,500

R35 · FY2021 · GM · contact PI

Large-scale profiling of microbial and metabolic interactions between C. difficile and gut microbiota using ultrahigh-throughput droplet microfluidics$194,375

R21 · FY2021 · AI · contact PI

Elucidating ecological mechanisms for propagation of antibiotic resistance genes via massively parallelized single-cell sequencing$194,167

R21 · FY2021 · AI · contact PI

Model-guided design of next-generation bacterial therapeutics to treat cardiovascular disease$697,498

R01 · FY2020 · EB · contact PI

Elucidating the molecular and ecological design principles of stability and assembly of the human gut microbiota$382,500

R35 · FY2020 · GM · contact PI

Elucidating the molecular and ecological design principles of stability and assembly of the human gut microbiota$10,732

R35 · FY2020 · GM · contact PI

Elucidating the molecular and ecological design principles of stability and assembly of the human gut microbiota$382,500

R35 · FY2019 · GM · contact PI

Elucidating the molecular and ecological design principles of stability and assembly of the human gut microbiota$382,500

R35 · FY2018 · GM · contact PI

Elucidating the molecular and ecological design principles of stability and assembly of the human gut microbiota$370,993

R35 · FY2017 · GM · contact PI